Rational design of oncocin derivatives with superior protease stabilities and antibacterial activities based on the high-resolution structure of the oncocin-DnaK complex
about
Insights into the molecular mechanism of allostery in Hsp70s.The Receptor for Advanced Glycation End Products (RAGE) Specifically Recognizes Methylglyoxal-Derived AGEsThe proline-rich antimicrobial peptide Onc112 inhibits translation by blocking and destabilizing the initiation complexDnaK as Antibiotic Target: Hot Spot Residues Analysis for Differential Inhibition of the Bacterial Protein in Comparison with the Human HSP70Novel peptide-protein assay for identification of antimicrobial peptides by fluorescence quenching.Development of second generation peptides modulating cellular adiponectin receptor responses.His-tag protein monitoring by a fast mix-and-measure immunoassay.Antimicrobial and immunomodulatory activities of PR-39 derived peptidesThe mechanism of inhibition of protein synthesis by the proline-rich peptide oncocinOptimization of oncocin for antibacterial activity using a SPOT synthesis approach: extending the pathogen spectrum to Staphylococcus aureus.Proline-rich antimicrobial peptides targeting protein synthesis.Novel apidaecin 1b analogs with superior serum stabilities for treatment of infections by gram-negative pathogens.Structures of proline-rich peptides bound to the ribosome reveal a common mechanism of protein synthesis inhibition.Hsp110 is a bona fide chaperone using ATP to unfold stable misfolded polypeptides and reciprocally collaborate with Hsp70 to solubilize protein aggregates.Database-Guided Discovery of Potent Peptides to Combat HIV-1 or SuperbugsIn vivo Efficacy and Pharmacokinetics of Optimized Apidaecin Analogs.The proteome targets of intracellular targeting antimicrobial peptides.Intracellular Targeting Mechanisms by Antimicrobial PeptidesInsect-derived short proline-rich and murine cathelicidin-related antimicrobial peptides act synergistically on Gram-negative bacteria in vitro.Immunogenicity and pharmacokinetics of short, proline-rich antimicrobial peptides.Intracellular toxicity of proline-rich antimicrobial peptides shuttled into mammalian cells by the cell-penetrating peptide penetratin.Ribosomal binding and antibacterial activity of ethylene glycol-bridged apidaecin Api137 and oncocin Onc112 conjugates.Pharmacokinetics and in vivo efficacy of optimized oncocin derivatives.Protein aggregation as an antibiotic design strategy.Oncocin Onc72 is efficacious against antibiotic-susceptible Klebsiella pneumoniae ATCC 43816 in a murine thigh infection model.Insect-derived proline-rich antimicrobial peptides kill bacteria by inhibiting bacterial protein translation at the 70S ribosome.Effect of antimicrobial peptides from Apis mellifera hemolymph and its optimized version Api88 on biological activities of human monocytes and mast cells.Correlating uptake and activity of proline-rich antimicrobial peptides in Escherichia coli.Controlled systemic release of therapeutic peptides from PEGylated prodrugs by serum proteases.Oncocin derivative Onc72 is highly active against Escherichia coli in a systemic septicaemia infection mouse model.
P2860
Q26779247-72F90659-0361-4D3F-84EC-1BD7128B928CQ27683771-678E74FA-3968-4AE5-B2F7-00DD0C5416CCQ27700868-8DE67D3B-DA5A-4A34-86FB-6FBC64C998D9Q28546662-8CC1A41D-6020-40B9-BD77-A908B9BEF677Q34262733-7633E9A0-B2B0-41B0-B5F1-6DA29EF1C1F1Q34360125-6E7A0F03-55AD-4651-890B-A0880A2440E5Q34428190-C7306389-FB29-47DB-B54C-140077E7D458Q35154887-8588F56B-35BC-4808-854B-8920B56D5D19Q35685002-C76CE40E-9BF2-40B5-B71D-F675589159F7Q35762892-B3566AF7-DDF9-4DDA-9896-2A7BC7010518Q36379116-B1719C8D-9DDC-41D5-9AB8-0F150EE0AA2FQ36505406-89FF756E-2B4B-4ABF-8A6A-47FA823DE7FEQ36701111-4B9A1608-8072-4157-912D-06AD368811DDQ37175214-D4F491DE-212C-4197-9DF8-5144CA4C2553Q37277482-D6FD2961-7943-4FFE-8A26-56AF7EA64A31Q37710376-52B7C789-CF5E-4A3E-ABD5-98A312D1B95FQ38663372-8CDECB3C-82C0-4E97-A183-D83C79AF650AQ38760670-EAF1DB93-8ED6-4B3C-A0F5-228C0633D908Q38855258-D664D5C5-30F0-4362-A05C-3102670D5885Q38970681-1A36EBFD-4B7F-40CF-8D33-AFEF60A9CDBAQ39304670-C90AAB39-100A-456C-BA21-624D61061DA7Q39608562-182C9006-625D-41D6-A338-FA6C18989CA2Q40809842-2C3A8152-6782-4B40-AA0A-CF0EB75CC756Q40913286-C41A719B-6101-4A8B-86B7-23CA7DD7D815Q41236257-DF8E9BBD-DFA1-4955-9342-B5397E059F68Q41739821-D62D1810-5472-481E-933E-BEEC46743F5DQ44220826-04B0F676-7C27-4246-9AA2-9D8876B20C78Q48111070-11F4BB13-3B4B-4BCB-9598-8260DCAFA547Q50908330-281ADAEF-BCEA-4498-89D6-EACD6E0338CBQ54333817-4388C928-B40F-4265-B75B-113FEF496072
P2860
Rational design of oncocin derivatives with superior protease stabilities and antibacterial activities based on the high-resolution structure of the oncocin-DnaK complex
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Rational design of oncocin der ...... re of the oncocin-DnaK complex
@ast
Rational design of oncocin der ...... re of the oncocin-DnaK complex
@en
Rational design of oncocin der ...... re of the oncocin-DnaK complex
@nl
type
label
Rational design of oncocin der ...... re of the oncocin-DnaK complex
@ast
Rational design of oncocin der ...... re of the oncocin-DnaK complex
@en
Rational design of oncocin der ...... re of the oncocin-DnaK complex
@nl
prefLabel
Rational design of oncocin der ...... re of the oncocin-DnaK complex
@ast
Rational design of oncocin der ...... re of the oncocin-DnaK complex
@en
Rational design of oncocin der ...... re of the oncocin-DnaK complex
@nl
P2093
P2860
P356
P1433
P1476
Rational design of oncocin der ...... re of the oncocin-DnaK complex
@en
P2093
Daniel Knappe
Guido Schiffer
Michael Zahn
Ralf Hoffmann
P2860
P356
10.1002/CBIC.201000792
P577
2011-04-11T00:00:00Z